Abstract
The retroviral vector is widely used in gene therapy, and it has shown its efficacy in the treatment of several infants with severe combined immunodeficiency (SCID)-X1. The current process for producing retroviral vectors with adherent packaging cell lines is costly, labor-intensive, and ineffective in producing high amount of vectors needed for clinical trials. The large-scale production of high- titer clinical grade retroviral vectors could benefit from retrovirus packaging cell lines that could grow in suspension and serum free media.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call